Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies

NCT01204164 is registered in ClinicalTrials.gov with Tragara Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01204164
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01204164 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Lead sponsor
Tragara Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2010
Completion date
April 30, 2016
Enrollment
120 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

all, aml, blast crisis, mds, multiple myeloma